Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF) patients could benefit from treatment for the first time. The company is a pioneer in ...

Shares of Vertex, Inc. (NASDAQ:VERX – Get Free Report) have received a consensus rating of “Moderate Buy” from the thirteen brokerages that are covering the stock, Marketbeat reports.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Investors eye Vertex’s Q1 for Alyftrek and Journavx momentum amid Trikafta’s international headwinds. Vertex stock shows a bullish technical bias despite recent pullback and mixed short-term ...

Tropical cyclones are dangerous storms that threaten lives, property and infrastructure. Our cyclone warning services help keep communities safe. For emergency assistance during a tropical cyclone, ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. One of these two impactful publications was issued by Swiss bank UBS analyst Eliana Merle. The second of the pair ...

ToolGen commences legal action in UK court over Vertex's genome editing therapy, CASGEVY ® Seeks to expand licensing of its proprietary CRISPR RNP technology SEOUL, South Korea, April 21 ...